Bio-Connect

Anti-CD32b [NOV1216], Human IgG1-STR, STR Fc silenced, lambda

AB03966-10.139
Absolute Antibody
ApplicationsFlow Cytometry, ELISA, Other Application
Product group Antibodies
ReactivityHuman
TargetFCGR2B
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Absolute Antibody
  • Product Name
    Anti-CD32b [NOV1216], Human IgG1-STR, STR Fc silenced, lambda
  • Delivery Days Customer
    9
  • Antibody Specificity
    The antibody specifically binds to CD32b. The antibody mainly recognizes epitope I (i.e. the Fc binding domain area). The antibody does not cross reacts with human CD32a-R.
  • Application Supplier Note
    The specificity of the antibody for CD32b was determined by ELISA analysis. The antibody was able to bind to CD32b expressed on human B cells by flow cytometry analysis (binding affinity 1.4 nM). The binding the antibody to the BJAB cell line was evaluated by flow cytometry (binding affinity = 2.4 nM). The antibody bound to CHO cells expressing huCD32b by flow cytometry analysis.The human IgG1 format of the antibody was evaluated for its activity in a primary NK cell based antibody-dependent cell-mediated cytotoxicity (ADCC) assay. The antibody demonstrated concentration dependent specific cell lysis of both cancer cell lines evaluated (Jeko-1 and Karpas422 Cancer Cell). The antibody showed a dose dependent in vivo efficacy in mice bearing established Daudi Xenografts. The ability of Fc WT, Fc enhanced and Fc silent versions of the antibody to bind CD32b positive target cells (such as DAUDI, ATCC CCL-213 and Jeko-1, DSMZ ACC533) and subsequently activate CD16a on Jurkat-NFAT v158 reporter cells was evaluated by the Jurkat-NFAT reporter assay. The Fc WT and the Fc enhanced versions yielded to CD16a activation. The Fc Silent version of the antibody enhanced CD16a activation by rituximab and obinutuzumab when CD32b and CD20 are co-expressed on the same target cells. The enhancement is believed to be due to blocking of CD32b binding to the Fc portion of rituximab and obinutuzumab (US20170198040A1).
  • Applications
    Flow Cytometry, ELISA, Other Application
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    NOV1216
  • Gene ID2213
  • Target name
    FCGR2B
  • Target description
    Fc fragment of IgG receptor IIb
  • Target synonyms
    CD32; CD32B; CDw32; Fc fragment of IgG, low affinity II, receptor for (CD32); Fc fragment of IgG, low affinity IIb, receptor (CD32); Fc fragment of IgG, low affinity IIb, receptor for (CD32); Fc gamma receptor IIb; Fc gamma RIIb; FCG2; fc-gamma RII-b; Fc-gamma RII-c; fc-gamma-RIIb; Fc-gamma-RIIc; FCGR2; FCGR2C; fcRII-b; FcRII-c; IGFR2; igG Fc receptor II-b; IgG Fc receptor II-c; low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c
  • Host
    Human
  • Isotype
    IgG1
  • Protein IDP31994
  • Protein Name
    Low affinity immunoglobulin gamma Fc region receptor II-b
  • Scientific Description
    This format contains the STR complete Fc Silencing mutations from mAbsolve. This is a reformatted human IgG1 STR Fc silenced antibody, based on the original human Fab format, created for improved compatibility with existing reagents, assays and techniques.
  • Reactivity
    Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203